Cancer Immunology, Immunotherapy

, Volume 58, Issue 5, pp 729–736 | Cite as

Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines

  • Xuede Lin
  • Xiaojian Wang
  • Haley L. Capek
  • Laura C. Simone
  • Amit Tuli
  • Chantey R. Morris
  • Adrian J. Reber
  • Joyce C. Solheim
Original Article


Invariant chain (Ii) binds to the human leukocyte antigen (HLA) class II molecule and assists it in the process of peptide acquisition. In addition, Ii binds to the HLA class I molecule, although there has been little study of its effects on the HLA class I molecule. In addition to its normal expression on antigen-presenting cells, Ii expression is up regulated in a variety of tumors. By flow cytometric analysis, we found that expression of Ii resulted in an increase in the number of cell surface HLA class I molecules and in the proportion of unstable HLA class I molecules at the surface of breast tumor cell lines. These data suggest that the expression of Ii by tumor cells may quantitatively and qualitatively alter the presentation of antigens on those cells.


Antigen presentation Breast cancer Antigens/peptides/epitopes Invariant chain MHC class I molecule 



The authors thank Austin Ahles for her assistance with this project. We also thank Dr. Shantaram Joshi, Dr. Kenneth Cowan, Dr. Vinod Labhasetwar, Dr. Michael A. Hollingsworth, Dr. Richard MacDonald, Christopher Connelly, Michelle Hartman, Jaspreet Vasir, Tom Caffrey, Dr. Pankaj Singh, Dr. Peter Cresswell and Dr. Ted Hansen for their assistance with obtaining cell lines, and Dr. Eric Long for the RSV.5neo Vector. We gratefully acknowledge the assistance of the personnel of the University of Nebraska Medical Center Cell Analysis Facility and the Monoclonal Antibody Facility. Core facilities at the University of Nebraska Medical Center receive support from the NIH/NCI Cancer Center Support Grant P30CA036727 (to the Eppley Cancer Center) and the Nebraska Research Initiative. This work was supported by NIH/NIGMS R01 Grant GM057428 and an LB506 Nebraska DHHS Cancer & Smoking Disease Research Grant (to J.C.S.), a Structural Biology and Biophysics Training Program Fellowship from the Department of Education Graduate Assistance in Areas of National Need Program (to H.L.C), NIH/NCI Training Grant T32 CA009476 Fellowship (to L.C.S.), UNMC Graduate Studies Fellowships (to L.C.S. and A.T.), NIH/NRSA Fellowship F32 AI055152 (to C.R.M.), and DOD Breast Cancer Training Program DAMD 17-00-1-0361 Fellowship (to A.J.R.).


  1. 1.
    Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB (1979) Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 282:615–616PubMedCrossRefGoogle Scholar
  2. 2.
    Armstrong TD, Clements VK, Ostrand-Rosenberg S (1998) Class II-transfected tumor cells directly present endogenous antigen to CD4+T cells in vitro and are APCs for tumor-encoded antigens in vivo. J Immunother 21:218–224PubMedCrossRefGoogle Scholar
  3. 3.
    Cailleau R, Olive M, Cruciger OV (1978) Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 17:911–915CrossRefGoogle Scholar
  4. 4.
    Carreno BM, Hansen TH (1994) Exogenous peptide ligand influences the expression and half-life of free HLA class I heavy chains ubiquitously detected at the cell surface. Eur J Immunol 24:1285–1292PubMedCrossRefGoogle Scholar
  5. 5.
    Cerundolo V, Elliott T, Elvin J, Bastin J, Townsend A (1992) Association of the human invariant chain with H-2Db class I molecules. Eur J Immunol 22:2243–2248PubMedCrossRefGoogle Scholar
  6. 6.
    Cormier JN, Panelli MC, Hackett JA, Bettinotti MP, Mixon A, Wunderlich J, Parker LL, Restifo NP, Ferrone S, Marincola FM (1999) Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer 80:781–790PubMedCrossRefGoogle Scholar
  7. 7.
    Cresswell P (1992) Chemistry and functional role of the invariant chain. Curr Opin Immunol 4:87–92PubMedCrossRefGoogle Scholar
  8. 8.
    Dahiya R, Kwak KS, Byrd JC, Ho S, Yoon WH, Kim YS (1993) Mucin synthesis and secretion in various human epithelial cancer cell lines that express the MUC-1 mucin gene. Cancer Res 53:1437–1443PubMedGoogle Scholar
  9. 9.
    De Silva AD, Boesteanu A, Song R, Nagy N, Harhaj E, Harding CV, Joyce S (1999) Thermolabile H-2 Kb molecules expressed by transporter associated with antigen processing-deficient RMA-S cells are occupied by low-affinity peptides. J Immunol 163:4413–4420PubMedGoogle Scholar
  10. 10.
    Fogh J, Wright WC, Loveless JD (1977) Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58:209–214PubMedGoogle Scholar
  11. 11.
    Iwamura T, Katsuki T, Ide K (1987) Establishment and characterization of a human pancreatic cancer cell lines (SUIT-2) producing caricnoembryonic antigen and carbohydrate antigen 19–9. Jpn J Cancer Res 78:54–62PubMedGoogle Scholar
  12. 12.
    Jabrane-Ferrat N, Faille A, Loiseau P, Poirier O, Charron D, Calvo F (1990) Effect of gamma interferon on HLA class-I and -II transcription and protein expression in human breast adenocarcinoma cell lines. Int J Cancer 45:1169–1176PubMedCrossRefGoogle Scholar
  13. 13.
    Jiang Z, Xu M, Savas L, LeClair P, Banner BF (1999) Invariant chain expression in colon neoplasms. Virch Arch 435:32–36CrossRefGoogle Scholar
  14. 14.
    Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M, Chaitcik S, Brenner HJ (1979) Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer 15:659–670PubMedGoogle Scholar
  15. 15.
    Koretz K, Moldenhauer G, Majdic O, Moller P (1989) Correlation of HLA-D/Ii antigen expression in breast carcinoma with local lymphohistiocytic infiltration reveals considerable dysregulation in a subset of tumors. Int J Cancer 44:816–822PubMedCrossRefGoogle Scholar
  16. 16.
    Long EO, Rosen-Bronson S, Karp DR, Malnati M, Sekaly RP, Jaraquemada D (1991) Efficient cDNA expression vectors for stable and transient expression of HLA-DR in transfected fibroblasts and lymphoid cells. Hum Immunol 31:229–235PubMedCrossRefGoogle Scholar
  17. 17.
    Moller P, Mattfeldt T, Gross C, Schlosshauer P, Koch A, Koretz K, Moldenhauer G, Kaufmann M, Otto HF (1989) Expression of HLA-A, -B, -C, -DR, -DP, -DQ, and of HLA-D-associated invariant chain (Ii) in non-neoplasmic mammary epithelium, fibroadenoma, adenoma, and carcinoma of the breast. Am J Pathol 135:73–83PubMedGoogle Scholar
  18. 18.
    Moller P, Koretz K, Schlag P, Momburg, F (1991) Frequency of abnormal expression of HLA-A,B,C and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumor recurrence. Int J Cancer (Suppl) 6:155–162Google Scholar
  19. 19.
    Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J (1982) Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res 42:3858–3863PubMedGoogle Scholar
  20. 20.
    Owens RB, Smith HS, Nelson-Rees WA, Springer EL (1976) Epithelial cell cultures from normal and cancerous human tissues. J Natl Cancer Inst 56:843–849PubMedGoogle Scholar
  21. 21.
    Ozato K, Hansen TH, Sachs DH (1980) Monoclonal antibodies to mouse MHC antigens. II. Antibodies to the H-2Ld antigen, the product of a third polymorphic locus of the mouse major histocompatibility complex. J Immunol 125:2473–2477PubMedGoogle Scholar
  22. 22.
    Parham P, Barnstable CJ, Bodmer WH (1979) Use of a monoclonal antibody (W6/32) in structural studies of HLA-A, B, C antigens. J Immunol 123:342–349PubMedGoogle Scholar
  23. 23.
    Parham P, Brodsky FM (1981) Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol 3:277–299PubMedCrossRefGoogle Scholar
  24. 24.
    Powis SJ (2006) CLIP-region mediated interaction of Invariant chain with MHC class I molecules. FEBS Lett 580:3112–3116PubMedCrossRefGoogle Scholar
  25. 25.
    Reber AJ, Turnquist HR, Thomas HJ, Lutz CT, Solheim JC (2002) Expression of invariant chain can cause an allele-dependent increase in the surface expression of MHC class I molecules. Immunogenetics 54:74–81PubMedCrossRefGoogle Scholar
  26. 26.
    Ribas A, Timmerman JM, Butterfield LH, Economou JS (2003) Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 24:58–61PubMedCrossRefGoogle Scholar
  27. 27.
    Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN, McBride WH, Economou JS, Butterfield LH (2004) Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 27:354–367PubMedCrossRefGoogle Scholar
  28. 28.
    Rivoltini L, Baracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB, Rosenberg SA, Marincola FM (1995) Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes. Cancer Res 55:3149–3157PubMedGoogle Scholar
  29. 29.
    Saito T, Kimura M, Kawasaki T, Sato S, Tomita Y (1997) MHC class II antigen-associated invariant chain on renal cell cancer may contribute to the anti-tumor immune response of the host. Cancer Lett 115:121–127PubMedCrossRefGoogle Scholar
  30. 30.
    Soule HD, Vazquez J, Long A, Albert S, Brennan M (1973) A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51:1409–1416PubMedGoogle Scholar
  31. 31.
    Stam NJ, Spits H, Ploegh HL (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 137:2299–2306PubMedGoogle Scholar
  32. 32.
    Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL (1990) HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 2:113–125PubMedCrossRefGoogle Scholar
  33. 33.
    Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF (1978) Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21:274–281PubMedCrossRefGoogle Scholar
  34. 34.
    Sugita M, Brenner MB (1995) Association of the invariant chain with major histocompatibility complex class I molecules directs trafficking to endocytic compartments. J Biol Chem 270:1443–1448PubMedCrossRefGoogle Scholar
  35. 35.
    Tsutsumida H, Swanson BJ, Singh PK, Caffrey TC, Kitajima S, Goto M, Yonezawa S, Hollingsworth MA (2006) RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clin Cancer Res 12:2976–2987PubMedCrossRefGoogle Scholar
  36. 36.
    Turnquist HR, Solheim JC (2001) Analysis of major histocompatibility complex class I interactions with endoplasmic reticulum proteins. Meth Mol Biol 156:165–173Google Scholar
  37. 37.
    Vezeridis MP, Meiner PA, Tibbetts LM, Doremus CM, Tzanakakis G, Calabresi P (1990) Heterogeneity of potential for hematogenous metastasis in a human pancreatic carcinoma. J Surg Res 48:51–55PubMedCrossRefGoogle Scholar
  38. 38.
    Vigna JL, Smith KD, Lutz CT (1996) Invariant chain association with MHC class I. J Immunol 157:4503–4510PubMedGoogle Scholar
  39. 39.
    Yewdell JW, Bennink JR (1989) Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes. Science 244:1072–1075PubMedCrossRefGoogle Scholar
  40. 40.
    Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS (2001) Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 158:1639–1651PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Xuede Lin
    • 1
    • 2
  • Xiaojian Wang
    • 1
  • Haley L. Capek
    • 1
  • Laura C. Simone
    • 1
  • Amit Tuli
    • 1
    • 3
  • Chantey R. Morris
    • 1
  • Adrian J. Reber
    • 4
  • Joyce C. Solheim
    • 1
    • 3
  1. 1.Eppley Institute for Research in Cancer and Allied DiseasesUniversity of Nebraska Medical CenterNEUSA
  2. 2.Department of ChemotherapyThe First Affiliated Hospital of Fujian Medical UniversityFuzhouPeople’s Republic of China
  3. 3.Department of Biochemistry and Molecular BiologyUniversity of Nebraska Medical CenterNEUSA
  4. 4.Department of Population HealthUniversity of GeorgiaAthensUSA

Personalised recommendations